TITLE

SWOT Analysis

PUB. DATE
September 2010
SOURCE
Menarini Group SWOT Analysis;Sep2010, p1
SOURCE TYPE
SWOT Analysis
DOC. TYPE
Article
ABSTRACT
The article presents an analysis of the strengths, weaknesses, opportunities and threats (SWOT) faced by the Menarini Group. Based in Florence, Italy, the company is a privately held group involved in the development and manufacture of pharmaceutical products, particularly for cardiovascular diseases, oncology, pain, inflammation and asthma. Information on the company's financial performance and contact details are also included.
ACCESSION #
54597861

 

Related Articles

  • OTC Pharmaceuticals Industry Profile: Russia.  // OTC Pharmaceuticals Industry Profile: Russia;Sep2015, p1 

    An industry report of the over-the-counter (OTC) pharmaceutical industry in Russia is presented from publisher Marketline, with topics including degree of rivalry in the OTC drugs market, market value forecast, and leading companies such as the Menarini Group.

  • Menarini Group Succeeds in Bid for Invida Group.  // Biomedical Market Newsletter;11/21/2011, Vol. 21, p833 

    The article reports on the successful bid of Florence, Italy-based Menarini Group to acquire one of the leading pharmaceutical sales companies Invida Group Private Ltd. of Singapore. Menarini will be expanding to other nations such as Singapore, Australia, China, and other nations in the...

  • Approved indication: chronic obstructive pulmonary disease.  // Australian Prescriber;Oct2014, Vol. 37 Issue 5, p172 

    The article offers information on the aclidinium bromide bronchodilator drug Bretaris Genuair from A Menarini.

  • Vivus Cozies Up to Menarini on ED Drug, but Whither Qsymia? Powers, Marie // BioWorld Today;7/10/2013, Vol. 24 Issue 130, p1 

    The article discusses a license and commercialization deal and separate supply agreement signed by biotechnology firm Vivus Inc. with the Italian pharmaceutical firm Menarini Group and its subsidiary Berlin-Chemie AG/Menarini to commercialize and market erectile dysfunction (ED) drug Spedra...

  • CV Therapeutics licenses angina drug to Menarini Group.  // PharmaWatch: Biotechnology;Oct2008, Vol. 7 Issue 10, p11 

    The article reports on the agreement entered into by a U.S.-based biopharmaceutical company CV Therapeutics Inc. that grants exclusive rights to Ranexa in Europe and other countries to the Menarini Group. It has granted rights to Menarini for Ranexa in 68 countries which include 27 countries of...

  • Furiex Pharmaceuticals and Menarini Announce License Agreement for Priligy(r).  // Biomedical Market Newsletter;5/18/2012, Vol. 21, p1 

    The article presents information on license agreement between Furiex Pharmaceuticals Inc. and Menarini Group. It mentions that the licensing will allow Menarini to commercialize priligy®, an oral medication of selective serotonin reuptake inhibitor (SSRI), in several areas including Europe,...

  • OBT AND BERLIN-CHEMIE/MENARINI DESIGNATE NOVEL ADC.  // Worldwide Biotech;Nov2014, Vol. 26 Issue 11, p1 

    The article discusses the selection of a novel antibody-drug conjugate (ADC) by Oxford BioTherapeutics (OBT) and Berlin Chemie/Menarini Group that targets Non-Hodgkin's B-Cell Lymphoma and solid tumours. The ADC candidate was identified by OBT's proprietary Oxford Genome Anatomy Project (OGAP)...

  • Keral.  // Royal Society of Medicine: Medicines;2002, p318 

    This article presents information on the drug Keral from Menarini. This is a proprietary, prescription-only preparation of the (nonsteroidal anti-inflammatory drug) and antirheumatic dexketoprofen (as trometamol), which can be used in the short-term treatment of mild to moderate pain including...

  • Biotechnology Industry Profile: Italy.  // Biotechnology Industry Profile: Italy;Aug2008, p1 

    Presents a profile of the Biotechnology industry in Italy. Executive summary of the industry; Market overview; Market value; Market segmentation; Competitive landscape; Leading companies in the industry; Market forecasts; Demographics; Further reading.

  • Biotechnology Industry Profile: Italy.  // Biotechnology Industry Profile: Italy;Jul2009, p1 

    Presents a profile of the Biotechnology industry in Italy. Executive summary of the industry; Market overview; Market value; Market segmentation; Competitive landscape; Leading companies in the industry; Market forecasts; Demographics; Further reading.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics